Aldose reductase inhibitors and their potential for the treatment of diabetic complications

doi:10.1016/0165-6147(94)90010-8

Trends in Pharmacological Sciences

Volume 15, Issue 8, August 1994, Pages 293-297

https://doi.org/10.1016/0165-6147(94)90010-8 Get rights and content

Abstract

Aldose reductase converts glucose to sorbitol, which is further processed to fructose. The enzyme is present in most tissues and its possible physiological role is to produce an electrically neutral, non-diffusible osmolyte in cells exposed to hypertonicity, as typified by the renal medullary cells of the loop of Henlé. The enzyme has a low affinity for glucose, and under normal conditions it processes tittle substrate. However, in diabetes mellitus, the marked rise in intracellular glucose that occurs in some cells causes-narked production of sorbitol. The increased flux and accumulation of sorbitol is damaging to cells and may result in some of the long-term complications of diabetes. In this review. David Tomlinson, Elizabeth Stevens and Lara Diemel discuss the role of aldose reductase and the potential of its inhibitors as therapeutic agents targeted at chronic diabetic complications.

References (42)

S.M. Bagnasco et al.
J. Biol. Chem.
(1986)
S. Edmands et al.
Comp. Biochem. Physiol.
(1992)
D.R. Tomlinson et al.
Pharmacol. Ther.
(1992)
R.N. Frank
Ophthalmology
(1991)
A. Lehmann et al.
FEBS Lett.
(1988)
R. Huby et al.
Exp. Eye Res.
(1988)
J.F. Jongkind et al.
Free Radical Biol. Med.
(1989)
L.A. Yeh et al.
Metabolism
(1990)
J.H. Kinoshita
Exp. Eye Res.
(1990)
P.A.R. Ekström et al.
J. Neurol. Sci.
(1989)

J.V. Santiago

J. Diab. Comp.

(1993)

D.R. Tomlinson et al.

Neurosci. Lett.

(1982)

A.A.F. Sima

J. Diab. Comp.

(1993)

G.N. Holcomb et al.

Diabatologia

(1974)

S.M. Bagnasco et al.

Am. J. Physiol.

(1988)

L-R. Lin et al.

Invest. Ophthalmol. Vis. Sci.

(1993)

M.J. Stevens

Diabetologia

(1993)

C.A. Bondy et al.

Mol. Endocrinol.

(1989)

T.C. Hohman et al.

Diabetologia

(1992)

R. Osterby

Diabetologia

(1992)

Diabetes Control and Complications Trial Research Group

New Engl. J. Med.

(1993)

Cited by (192)

Algal metabolites: Paving the way towards new generation antidiabetic therapeutics
2023, Algal Research
Citation Excerpt :
PTP1B inhibitors inhibit the PTP1B mediated dephosphorylation of the insulin receptor and protect it from deactivation [388]. Whereas, aldose reductase inhibitors are agents that block glucose metabolism into harmful products [41], and agents that block gluconeogenesis are phosphoenolpyruvate carboxykinase inhibitors (PEPCK) [42] and fructose-1,6-bisphosphatase inhibitors (FBPase) [43]. Further, biguanides inhibit liver gluconeogenesis which results in the treatment of hyperglycemia [44].
Diabetes is prevailing in pandemic proportions, as nearly half a billion population is affected by diabetes worldwide. The expenditure on diabetes healthcare is estimated to grow to $845 billion by 2045. However, identifying an efficient drug for completely curing diabetes and its complications is still unattainable. Given these challenges, we have discussed the range of storage molecules and pigments derived from microalgae, macroalgae, and cyanobacteria and explored their promising potential as antidiabetic drugs. Further, in silico studies have also been investigated for elucidating plausible molecular mechanisms of the most promising algal compounds. It is noteworthy that the chemical synthesis of bulky compounds is a cumbersome and less efficient process, whereas naturally occurring bulky compounds have complex stereospecific ornamentation of chemical groups executed by the number of stereospecific enzymes. On the other hand, growing algae in controlled conditions is an easy method to get various algal metabolites with a diverse array of chemical structures exhibiting pleiotropic antidiabetic activities. This review highlights the promising potential of algal metabolites to treat diabetes by targeting a variety of molecular mechanisms involved in the pathogenesis of diabetes.
Role of pyridines as enzyme inhibitors in medicinal chemistry
2022, Recent Developments in the Synthesis and Applications of Pyridines
Medicinal chemists are investigating new methods for the synthesis of alternative scaffolds that can be used as chemotherapeutic agents in the field of medicinal chemistry. Nitrogen-containing heterocycles are well known for their numerous biological activities and play a pivotal role in current drug design and discovery. Among them, pyridine and pyridine-based molecules are privileged pharmacophores that are present in numerous natural products and are tremendously important in biological systems. This electron-deficient heterocycle is present in the important vitamins and in the marketed drugs such as nexium, takepron, actos, etc. Substituted pyridines are reported as anticancer, anti-inflammatory, antifungal, antiproliferative, antitumor, antimicrobial, antitubercular, anti-HIV, and enzyme inhibitors. Inhibition of enzymes is a promising therapeutic strategy to improve a metabolic imbalance or kill a pathogen. Enzyme inhibitors interact with enzymes in a way (temporary or permanent) that prevent the enzymes from functioning normally and decrease the rate of an enzyme-catalyzed reaction. Many of the pyridine drugs are enzyme inhibitors such as indinavir, milrinone, and nevirapine. Promising results with the pyridinyl moiety open up the door for the development of a new generation of inhibitors. This chapter aims to review the progress in enzyme inhibition by pyridine-heterocyclic systems. Due to numerous bioactivities of pyridine-based compounds, they are involved in the drug designing and development process for screening them against diversified therapeutic targets. Among them, several classes of pyridine-based molecules inhibit a variety of clinically important enzymes.
Design, synthesis and biological evaluation of selective hybrid coumarin-thiazolidinedione aldose reductase-II inhibitors as potential antidiabetics
2021, Bioorganic Chemistry
Thiazolidinediones (TZD), benzopyrans are the proven scaffolds for inhibiting Aldose reductase (ALR2) activity and their structural confluence with the retention of necessary fragments helped in designing a series of hybrid compounds 2-(5-cycloalkylidene-2,4-dioxothiazolidin-3-yl)-N-(2-oxo-2H-chromen-3-yl)acetamide (10a-n) for better ALR2 inhibition. The compounds were synthesized by treating substituted 3-(N-bromoacetyl amino)coumarins (9a-d) with potassium salt of 5-cyclo alkylidene-1,3-thiazolidine-2,4-diones (4a-d). The inhibition activity against ALR2 with IC₅₀ values range from 0.012 ± 0.001 to 0.056 ± 0.007 μM. N-[(6-Bromo-3-coumarinyl)-2-(5-cyclopentylidene-2,4-dioxothiazolidin-3-yl)] acetamide (10c) with cyclopentylidene group on one end and the 6-bromo group on the other end showed better inhibitory property (IC₅₀ = 0.012 μM) and selectivity index (324.166) against the ALR2, a forty fold superiority over sorbinil, a better molecule over epalrestat and rest of the analogues exhibited a far superior response over sorbinil and slightly better as compared with epalrestat. It was further confirmed by the insilico studies that compound 10c showed best inhibition activity among the synthesized compounds with a high selectivity index against the ALR2. In invivo experiments, supplementation of compound 10c to STZ induced rats delayed the progression of cataract in a dose-dependent manner warranting its further development as a potential agent to treat the diabetic secondary complications especially cataract.
An extensive research on aldose reductase inhibitory effects of new 4H-1,2,4-triazole derivatives
2021, Journal of Molecular Structure
Aldose reductase (AR) is a key enzyme, which triggers the excessive accumulation of sorbitol in insulin independent tissues leading to severe diabetes-induced microvascular complications. Substantial evidence has proven that AR inhibition is a well-established strategy to attenuate these complications. In the current work, new 2-[(4-amino-5-aryl-4H-1,2,4-triazol-3-yl)thio]-N-(thiazol/benzothiazol-2-yl)acetamides (1–18) were synthesized and evaluated for their inhibitory capacities on AR. 2-[(4-Amino-5-(4-methylphenyl)-4H-1,2,4-triazol-3-yl)thio]-N-(5-nitrothiazol-2-yl)acetamide (12) and 2-[(4-amino-5-(3-pyridyl)-4H-1,2,4-triazol-3-yl)thio]-N-(6-nitrobenzothiazol-2-yl)acetamide (17) were identified as the most effective AR inhibitors in this series with the K_i values of 0.04 ± 0.01 µM and 0.08 ± 0.02 µM, respectively as compared to quercetin (K_i = 5.66 ± 0.66 μM). These two compounds displayed competitive AR inhibition. MTT assay, a tetrazolium-based cell viability assay, was performed to determine the cytotoxic effects of compounds 1–18 on L929 mouse fibroblast (healthy) cell line. Compounds 1–18, except for compounds 10, 13, 14, 15 and 16, were found nontoxic against healthy cells. Besides, molecular docking studies were fundamentally in agreement with the biological data with regard to essential π-π interactions with Trp219, Phe122 and Trp111 residues in the active site of AR. Eventually, in vitro and in silico assays ascertain that in particular compounds 12 and 17 will attract a great notice as drug-like AR inhibitors for further investigations related to amelioration of long-term diabetic complications.
Glucopyranoside flavonoids isolated from leaves of Spinacia oleracea (spinach) inhibit the formation of advanced glycation end products (AGEs) and aldose reductase activity (RLAR)
2020, Biomedicine and Pharmacotherapy
Citation Excerpt :
AR inhibition is an important strategy for the attenuation and prevention of long-term diabetic complications. Natural AR inhibitors are being investigated as potential therapeutic agents in diabetic complications [5]. Zebrafish has been established as an excellent animal model to evaluate pathological and physiological conditions in humans [6].
The formation and accumulation of advanced glycation end products (AGEs) and rat lens aldose reductase (RLAR) generated in the glycation process play an outstanding role in the complications of diabetes. Owing to the adverse effects of AGEs on diabetic patients, the search for new anti-AGE agents from plants without side effects has had significant interest from the researchers in the last decades for the development of a therapy that improves diabetic complications. Spinach could reverse the formation of AGEs and RLAR. This study aimed to investigate the ability of 10 known glucopyranosides flavonoids isolated from Spinacia oleracea on the formation of AGEs and RLAR in vitro and in vivo experiments.
Methanol extract of leaves of spinach was subjected to bioassay-guided fractionation using to silica gel column chromatographic followed by gel filtration by Sephadex LH-20. BSA glucose system and in vitro bioassays using rat lens aldose reductase (RLAR) were employed to evaluated inhibitory activity on the formation of AGEs. The induced diabetes in zebrafish by immersing in a 111 mM glucose solution for 14 days, revealed increased glycation of proteins in the eyes. Measurements of glycated hemoglobin and fructosamine were used to verify the anti-AGEs effect of the isolated flavonoids.
Through bioassay-guided fractionation of methanol extract of leaves spinach, ten known glucopyranoside flavonoids (1-10) have been isolated, and spectroscopic studies established their structures. Among the isolated compounds are: patuletin-3-O-(2”-coumaroylglucosyl)-(1→6)-[apiosyl-(1→2)]- β-d-glucopyranoside (7), patuletin 3-O-(2”-feruloyl glucosyl)-(1→6)-[apiosyl-(1→2)]- β-d-glucopyranoside (8), they have shown potent inhibition on AGEs formation, stronger than the positive controls used in the different experiments.
The findings indicated that glucopyranoside flavonoids found in Spinacia oleracea might have therapeutic potential for decreasing protein glycation, and might ameliorate AGE-related diabetic complications.
Didymin, a dietary citrus flavonoid exhibits anti-diabetic complications and promotes glucose uptake through the activation of PI3K/Akt signaling pathway in insulin-resistant HepG2 cells
2019, Chemico-Biological Interactions
Didymin is a naturally occurring orally active flavonoid glycoside (isosakuranetin 7-O-rutinoside) found in various citrus fruits, which has been previously reported to possess a wide variety of pharmacological activities including anticancer, antioxidant, antinociceptive, neuroprotective, hepatoprotective, inflammatory, and cardiovascular. However, there have not been any reports concerning its anti-diabetic potential until now. Therefore, we evaluated the anti-diabetic potential of didymin via inhibition of α-glucosidase, protein tyrosine phosphatase 1B (PTP1B), rat lens aldose reductase (RLAR), human recombinant AR (HRAR), and advanced glycation end-product (AGE) formation inhibitory assays. Didymin strongly inhibited PTP1B, α-glucosidase, HRAR, RLAR, and AGE in the corresponding assays. Kinetic study revealed that didymin exhibited a mixed type inhibition against α-glucosidase and HRAR, while it competitively inhibited PTP1B and RLAR. Docking simulations of didymin demonstrated negative binding energies and close proximity to residues in the binding pocket of HRAR, RLAR, PTP1B and α-glucosidase, indicating that didymin have high affinity and tight binding capacity towards the active site of these enzymes. Furthermore, we also examined the molecular mechanisms underlying the anti-diabetic effects of didymin in insulin-resistant HepG2 cells which significantly increased glucose uptake and decreased the expression of PTP1B in insulin-resistant HepG2 cells. In addition, didymin activated insulin receptor substrate (IRS)-1 by increasing phosphorylation at tyrosine 895 and enhanced the phosphorylations of phosphoinositide 3-kinase (PI3K), Akt, and glycogen synthasekinase-3(GSK-3). Interestingly, didymin reduced the expression of phosphoenolpyruvate carboxykinase and glucose 6-phosphatase, two key enzymes involved in the gluconeogenesis and leading to a diminished glucose production. The results of the present study clearly demonstrated that didymin will be useful for developing multiple target-oriented therapeutic modalities for treatment of diabetes, and diabetes-associated complications.

View all citing articles on Scopus

View full text

Trends in Pharmacological Sciences

ReviewsAldose reductase inhibitors and their potential for the treatment of diabetic complications

Abstract

J. Biol. Chem.

Comp. Biochem. Physiol.

Pharmacol. Ther.

Ophthalmology

FEBS Lett.

Exp. Eye Res.

Free Radical Biol. Med.

Metabolism

Exp. Eye Res.

J. Neurol. Sci.

J. Diab. Comp.

Neurosci. Lett.

J. Diab. Comp.

Diabatologia

Am. J. Physiol.

Invest. Ophthalmol. Vis. Sci.

Diabetologia

Mol. Endocrinol.

Diabetologia

Diabetologia

New Engl. J. Med.

Reviews
Aldose reductase inhibitors and their potential for the treatment of diabetic complications